(Q33366311)

26 July 2017

title

A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer (English)

1 reference

multicenter clinical trial

26 July 2017

main subject

0 references

1 reference

1 reference

1 reference

S K Gupta

1

1 reference

26 July 2017

S John

2

1 reference

26 July 2017

R Naik

3

1 reference

26 July 2017

R Arora

4

1 reference

26 July 2017

B Selvamani

5

1 reference

26 July 2017

J Fuloria

6

1 reference

26 July 2017

N Ganesh

7

1 reference

26 July 2017

B S Awasthy

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

26 July 2017

1 reference

26 July 2017

volume

98

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

134-140

1 reference

26 July 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.032

Treatment of advanced epithelial ovarian cancer: past, present and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.032

Surgical management of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.032

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.032

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.032

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.032

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.032

Second-line treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.032

Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.032

Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.032

Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.032

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.032

10.1016/J.YGYNO.2005.03.032

7 January 2021

Identifiers

DOI

1 reference

26 July 2017

1 reference